Search research articles
Contact Us
Filters
Showing results (1-10 of 114) with videos related to
Page
of 12
Sort By:
Future Medicinal Chemistry
|
August 1, 2014
What is the future of bromodomains in targeted drug development?
Oleg Fedorov
Nature Chemical Biology
|
February 16, 2010
The (un)targeted cancer kinome
Oleg Fedorov, Susanne Müller, Stefan Knapp
Methods in Molecular Biology (Clifton, N.J.)
|
October 1, 2011
Kinase inhibitor selectivity profiling using differential scanning fluorimetry
Oleg Fedorov, Frank H Niesen, Stefan Knapp
Drug Discovery Today
|
May 1, 2007
Insights for the development of specific kinase inhibitors by targeted structural genomics
Oleg Fedorov, Michael Sundström, Brian Marsden, et al.
Proteins
|
April 9, 2008
RhoB can adopt a Mg2+ free conformation prior to GEF binding
Meera Soundararajan, Andrew Turnbull, Oleg Fedorov, et al.
Cell Chemical Biology
|
December 20, 2016
CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation
Heidi Olzscha, Oleg Fedorov, Benedikt M Kessler, et al.
Journal of Medicinal Chemistry
|
August 14, 2020
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity
Martin Schröder, Alex N Bullock, Oleg Fedorov, et al.
Mabs
|
March 18, 2017
Development of a monoclonal anti-ADAMTS-5 antibody that specifically blocks the interaction with LRP1
Salvatore Santamaria, Oleg Fedorov, John McCafferty, et al.
Chembiochem : a European Journal of Chemical Biology
|
July 29, 2009
Propionate analogues of zearalenone bind to Hsp90
Markus Ugele, Florenz Sasse, Stefan Knapp, et al.
Lipid Insights
|
October 4, 2014
Stimulation of Hepatic Apolipoprotein A-I Production by Novel Thieno-Triazolodiazepines: Roles of the Classical Benzodiazepine Receptor, PAF Receptor, and Bromodomain Binding
Herman J Kempen, Daniel Bellus, Oleg Fedorov, et al.
Page
of 12
Search research articles
Search
Showing results (1-10 of 114) with videos related to
Sort By:
Page
of 12
Future Medicinal Chemistry
|
August 1, 2014
What is the future of bromodomains in targeted drug development?
Oleg Fedorov
Nature Chemical Biology
|
February 16, 2010
The (un)targeted cancer kinome
Oleg Fedorov, Susanne Müller, Stefan Knapp
Methods in Molecular Biology (Clifton, N.J.)
|
October 1, 2011
Kinase inhibitor selectivity profiling using differential scanning fluorimetry
Oleg Fedorov, Frank H Niesen, Stefan Knapp
Drug Discovery Today
|
May 1, 2007
Insights for the development of specific kinase inhibitors by targeted structural genomics
Oleg Fedorov, Michael Sundström, Brian Marsden, et al.
Proteins
|
April 9, 2008
RhoB can adopt a Mg2+ free conformation prior to GEF binding
Meera Soundararajan, Andrew Turnbull, Oleg Fedorov, et al.
Cell Chemical Biology
|
December 20, 2016
CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation
Heidi Olzscha, Oleg Fedorov, Benedikt M Kessler, et al.
Journal of Medicinal Chemistry
|
August 14, 2020
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity
Martin Schröder, Alex N Bullock, Oleg Fedorov, et al.
Mabs
|
March 18, 2017
Development of a monoclonal anti-ADAMTS-5 antibody that specifically blocks the interaction with LRP1
Salvatore Santamaria, Oleg Fedorov, John McCafferty, et al.
Chembiochem : a European Journal of Chemical Biology
|
July 29, 2009
Propionate analogues of zearalenone bind to Hsp90
Markus Ugele, Florenz Sasse, Stefan Knapp, et al.
Lipid Insights
|
October 4, 2014
Stimulation of Hepatic Apolipoprotein A-I Production by Novel Thieno-Triazolodiazepines: Roles of the Classical Benzodiazepine Receptor, PAF Receptor, and Bromodomain Binding
Herman J Kempen, Daniel Bellus, Oleg Fedorov, et al.
Page
of 12